利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.029 秒)

    ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
    3.
    发明申请
    ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME 审中-公开
    腺苷受体拮抗剂及其制备和使用方法

    公开(公告)号：US20090221821A1

    公开(公告)日：2009-09-03

    申请号：US12368469

    申请日：2009-02-10

    申请人： Carol L. Ensinger ,  James E. Dowling ,  Russell C. Petter ,  Gnanasambandam Kumaravel

    发明人： Carol L. Ensinger ,  James E. Dowling ,  Russell C. Petter ,  Gnanasambandam Kumaravel

    IPC分类号： C07D473/04

    CPC分类号： C07D473/06 ,  C07D473/22 ,  C07F9/65616

    摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.In one embodiment, the invention features a compound of formula I:

    摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统的退行性疾病，呼吸系统疾病以及适合利尿治疗的许多疾病。 在一个实施方案中，本发明的特征在于式I的化合物：

    Adenosine receptor antagonists and methods of making and using the same
    5.
    发明授权
    Adenosine receptor antagonists and methods of making and using the same 失效
    腺苷受体拮抗剂及其制备和使用方法

    公开(公告)号：US06605600B1

    公开(公告)日：2003-08-12

    申请号：US09711554

    申请日：2000-11-13

    申请人： Carol L. Ensinger ,  James E. Dowling ,  Russell C. Petter ,  Gnanasambandam Kumaravel

    发明人： Carol L. Ensinger ,  James E. Dowling ,  Russell C. Petter ,  Gnanasambandam Kumaravel

    IPC分类号： C07D47306

    CPC分类号： C07D473/02 ,  C07D473/04 ,  C07D473/06

    摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: R3 is an optionally substituted group selected from: and wherein X1, X2, Z, R1, R2, and R6 are as described in the specification.

    摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环障碍，中枢神经系统的退行性疾病，呼吸系统疾病以及许多适用于利尿剂治疗的疾病。在一个实施方案中，本发明 具有式I化合物：R 3是选自以下的任选取代的基团：其中X 1，X 2，Z，R 1，R 2和R 6如说明书中所述。